《大行報告》高盛首予醫渡科技(02158.HK)「中性」評級 目標價67元
醫渡科技(02158.HK)於上月中在港上市,作為聯席保薦人的高盛發表報告表示,醫渡為內地人工智能/大數據行業的龍頭企業,於2019年高度分散的市場佔有率為5%,公司能夠幫助醫療保健公司/用戶從數據中獲取更深刻的見解,令他們提高效率。
該行預期,在其獨特的定位下,公司能擴大其客戶群、增加經常性/維持收入並吸引新客戶,料其2020至2023年度收入及淨利潤年複合增長率分別為80%及92%,首予「中性」評級及目標價67元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.